Register today for one of two in-depth workshops happening before the kick-off of KHI's Annual Stakeholders Meeting. The workshops will be
held simultaneously on Wednesday, September 6, 2023, from 1:00 - 3:30 pm EDT
at the Grand Hyatt Washington, D.C. Spots are limited, and registration is
currently open to KHI members only. Non-KHI members will be waitlisted.
*UPDATE: Registration is now closed for the pre-workshops. If you have any concerns, please email email@example.com.*
APOL1 Kidney Disease: A Roadmap from
Community Awareness and Screening to Clinical Trial Participation
Join the launch
of KHI's APOL1 Kidney Disease Roadmap to the kidney community. APOL1 is a
disease that disproportionately impacts people with recent African ancestry.
This discussion and workshop will highlight roadmap action items and ways to
increase disease awareness, increase genetic testing, and improve clinical
study participation. This focus on APOL1 Kidney Disease provides a foundation
for other kidney diseases where clinical trial enrollment and participation remain challenging. This workshop aims to gather your thoughts and experiences
to inform how KHI can further engage community-based organizations. Registered
workshop participants will receive an early copy of the roadmap.
trials conducted in the last few years have demonstrated that SGLT2
Inhibitors are safe and effective at slowing the rate of progression of kidney
diseases ranging from diabetic kidney disease to IgA nephropathy. When added to
the current standard of care, these drugs lower the risk of kidney failure
and death. However, these clinical trials were
conducted in adult patients. It is unknown if the significant health benefits
of SGLT2 inhibitors apply to pediatric patients with chronic kidney disease. In July 2023, together with KHI member, NephCure, and key stakeholders from
the United States and Europe, KHI organized a workshop to discuss the need
for clinical trials of SGLT2 inhibitors in pediatric chronic kidney
disease. This session will highlight the key conclusions of the workshop. It will solicit input from the KHI community on how to foster awareness of the
need for clinical trials of SGLT2 inhibitors in the pediatric nephrology
community and patient populations and how to maximize the feasibility of
these studies. Registered workshop participants will receive updates from the
joint NephCure workshop to help prepare for this discussion.